Total Payments
$36,485
2024 Payments
$4,842
Companies
6
Transactions
43
Medicare Patients
269
Medicare Billing
$50,593
Payment Breakdown by Category
Consulting$24,875 (68.2%)
Research$6,689 (18.3%)
Travel$3,682 (10.1%)
Food & Beverage$1,239 (3.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $24,875 | 10 | 68.2% |
| Unspecified | $6,689 | 11 | 18.3% |
| Travel and Lodging | $3,682 | 10 | 10.1% |
| Food and Beverage | $1,239 | 12 | 3.4% |
Payments by Type
General
$29,796
32 transactions
Research
$6,689
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $18,420 | 15 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $7,386 | 17 | $0 (2021) |
| Amgen Inc. | $4,842 | 5 | $0 (2024) |
| Genentech, Inc. | $3,676 | 4 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $2,040 | 1 | $0 (2023) |
| AbbVie, Inc. | $120.91 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,842 | 5 | Amgen Inc. ($4,842) |
| 2023 | $2,116 | 2 | Alexion Pharmaceuticals, Inc. ($2,040) |
| 2022 | $600.00 | 1 | Genentech, Inc. ($600.00) |
| 2021 | $10,065 | 5 | Genentech USA, Inc. ($5,190) |
| 2020 | $3,782 | 4 | Genentech USA, Inc. ($2,295) |
| 2019 | $13,484 | 18 | Genentech USA, Inc. ($10,935) |
| 2018 | $670.30 | 1 | NOVARTIS PHARMACEUTICALS CORPORATION ($670.30) |
| 2017 | $926.03 | 7 | Novartis Pharmaceuticals Corporation ($926.03) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/28/2024 | Amgen Inc. | UPLIZNA (Biological) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/28/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $1,106.85 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/28/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $847.50 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/28/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $112.78 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/28/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/13/2023 | Genentech, Inc. | Enspryng (Biological) | Food and Beverage | In-kind items and services | $75.61 | General |
| Category: Immunology | ||||||
| 01/03/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $2,040.00 | General |
| Category: Rare Disease | ||||||
| 03/14/2022 | Genentech, Inc. | OCREVUS (Biological) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: Immunology | ||||||
| 11/30/2021 | Genentech USA, Inc. | Enspryng (Biological) | Consulting Fee | Cash or cash equivalent | $2,295.00 | General |
| Category: Immunology | ||||||
| 11/19/2021 | Genentech, Inc. | OCREVUS (Biological) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 10/21/2021 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | — | In-kind items and services | $1,875.00 | Research |
| Study: A 12 MONTH PROSPECTIVE MULTICENTER TWO COHORT NONRANDOMIZED OPEN LABEL STUDY IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RMS TO INVESTIGATE CHANGES IN IMMUNE PHENOTYPE BIOMARKERS AFTER TREATMENT WITH 05MG FINGOLIMOD FLUENT • Category: NEUROSCIENCE | ||||||
| 05/07/2021 | Genentech, Inc. | Enspryng (Biological) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Immunology | ||||||
| 03/16/2021 | Genentech USA, Inc. | OCREVUS (Biological) | Consulting Fee | Cash or cash equivalent | $2,895.00 | General |
| Category: Immunology | ||||||
| 10/01/2020 | Genentech USA, Inc. | Enspryng (Biological) | Consulting Fee | Cash or cash equivalent | $2,295.00 | General |
| Category: Immunology | ||||||
| 09/11/2020 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | — | In-kind items and services | $614.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: NEUROSCIENCE | ||||||
| 07/15/2020 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | — | In-kind items and services | $259.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: NEUROSCIENCE | ||||||
| 02/27/2020 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | — | In-kind items and services | $614.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: NEUROSCIENCE | ||||||
| 10/21/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | — | In-kind items and services | $208.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: NEUROSCIENCE | ||||||
| 10/19/2019 | Genentech USA, Inc. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $244.60 | General |
| Category: None | ||||||
| 10/18/2019 | Genentech USA, Inc. | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: None | ||||||
| 10/18/2019 | Genentech USA, Inc. | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $338.20 | General |
| Category: None | ||||||
| 10/18/2019 | Genentech USA, Inc. | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $276.64 | General |
| Category: None | ||||||
| 10/18/2019 | Genentech USA, Inc. | Non-Covered Product (Drug) | Travel and Lodging | Cash or cash equivalent | $154.19 | General |
| Category: None | ||||||
| 10/18/2019 | Genentech USA, Inc. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $66.60 | General |
| Category: None | ||||||
| 10/18/2019 | Genentech USA, Inc. | Non-Covered Product (Drug) | Food and Beverage | Cash or cash equivalent | $39.23 | General |
| Category: None | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,428 | 5 |
| A 12 MONTH PROSPECTIVE MULTICENTER TWO COHORT NONRANDOMIZED OPEN LABEL STUDY IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RMS TO INVESTIGATE CHANGES IN IMMUNE PHENOTYPE BIOMARKERS AFTER TREATMENT WITH 05MG FINGOLIMOD FLUENT | Novartis Pharmaceuticals Corporation | $1,875 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,487 | 3 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $899.50 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 61 | 113 | $61,164 | $13,343 |
| 2022 | 2 | 73 | 117 | $71,566 | $14,284 |
| 2021 | 4 | 101 | 157 | $83,509 | $17,929 |
| 2020 | 1 | 34 | 51 | $29,099 | $5,037 |
Total Patients
269
Total Services
438
Medicare Billing
$50,593
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 61 | 113 | $61,164 | $13,343 | 21.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 59 | 103 | $63,510 | $12,289 | 19.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 14 | 14 | $8,056 | $1,995 | 24.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 60 | 114 | $65,034 | $13,985 | 21.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $6,314 | $2,629 | 41.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 14 | 14 | $8,768 | $925.10 | 10.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 11 | 13 | $3,393 | $389.61 | 11.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 34 | 51 | $29,099 | $5,037 | 17.3% |
About Dr. May Han, MD
Dr. May Han, MD is a Neurology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/29/2009. The National Provider Identifier (NPI) number assigned to this provider is 1285960005.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. May Han, MD has received a total of $36,485 in payments from pharmaceutical and medical device companies, with $4,842 received in 2024. These payments were reported across 43 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($24,875).
As a Medicare-enrolled provider, Han has provided services to 269 Medicare beneficiaries, totaling 438 services with total Medicare billing of $50,593. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Stanford, CA
- Active Since 10/29/2009
- Last Updated 10/29/2009
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1285960005
Products in Payments
- Non-Covered Product (Drug) $10,935
- GILENYA (Drug) $7,298
- Enspryng (Biological) $6,166
- OCREVUS (Biological) $4,995
- UPLIZNA (Biological) $4,842
- ULTOMIRIS (Biological) $2,040
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Stanford
Gregory Albers, Md, MD
Neurology — Payments: $500,221
Neurology $500,221
John Day, Md, MD
Neurology — Payments: $367,934
Neurology $367,934
Robert Cowan, Md, MD
Neurology — Payments: $253,351
Neurology $253,351
Josef Parvizi, Md, Phd, MD, PHD
Neurology — Payments: $215,697
Neurology $215,697
Chitra Venkatasubramanian, Md, MD
Neurology — Payments: $206,735
Neurology $206,735
Babak Razavi, M.d., Ph.d, M.D., PH.D
Neurology — Payments: $121,290
Neurology $121,290